EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Infliximab therapy for Crohns disease The Crohns and colitis center of New Jersey experience



Infliximab therapy for Crohns disease The Crohns and colitis center of New Jersey experience



Gastroenterology 118(4 Suppl 2 Part 2): AGA A1334, April




(PDF emailed within 0-6 h: $19.90)

Accession: 035130737

Download citation: RISBibTeXText

DOI: 10.1016/S0016-5085(00)81203-2



Related references

The 10-year experience with purinethol at the Crohns and Colitis Center of New Jersey. Gastroenterology 120(5 Supplement 1): A 623, April, 2001

Crohns disease of the colon part 4 clinical features of crohns ileo colitis. American Journal of Gastroenterology 64(3): 191-199, 1975

Long term outcome of top-down therapy in Crohns disease: A single-center experience. Inflammatory Bowel Diseases 17: S49-S50, 2011

Infliximab for Crohns Disease One units experience. Gut 50(Supplement 2): A76, April, 2002

Assessment of infliximab utilization for Crohns disease and Ulcerative Colitis patients across different sites-of-care. Inflammatory Bowel Diseases 17: S38-S39, 2011

Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-a, in the treatment of Crohns disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy?. Internal Medicine Journal 31(3): 146-150, 2001

Infliximab for Crohns Disease: More Than 13 Years of Real-world Experience. Inflammatory Bowel Diseases 24(3): 490-501, 2018

Infliximab therapy for fistulizing Crohns disease. American Journal of Gastroenterology 95(9): 2635, September, 2000

Infliximab in Crohns disease An office-based gastroenterologists community experience. American Journal of Gastroenterology 95(9): 2495, September, 2000

Treatment of Crohns disease with infliximab An initial community practice experience. Gastroenterology 118(4 Suppl 2 Part 1): AGA A567, April, 2000

Preliminary clinical experience with Infliximab in the treatment of refractory and fistulizing Crohns disease. Gastroenterology 118(4 Suppl 2 Part 1): AGA A565, April, 2000

Infliximab treatment for Crohns disease treated with elemental diet The Tokyo experience. American Journal of Gastroenterology 98(9 Supplement): S252-S253, September, 2003

Collaborative experience of open-label infliximab in refractory pediatric Crohns disease. JPGN 31(Supplement 2): S227, 2000

Infliximab in clinical routine: experience with Crohns disease and biomarkers of inflammation over 5 years. European Journal of Gastroenterology & Hepatology 21(10): 1168-1176, 2009

Crohns colitis with carcinoma and dysplasia a case and a review of 100 small and large bowel resections for crohns disease to detect incidence of dysplasia. American Journal of Surgical Pathology 7(2): 151-160, 1983